Backed by up to £80 million, a new UK public-body initiative is funding nine technology projects to accelerate memory disorder diagnoses. The UK Research and Innovation programme aims to raise the proportion of patients diagnosed within 18 weeks of referral from around 60% to 92%, targeting a process that can currently take over a year.
UK Research and Innovation Targets a 92% Diagnostic Rate
More people die as a consequence of dementia than any other disease in the United Kingdom, accounting for almost one in eight deaths according to medical figures. In 2025, over 72,000 people across the UK died from dementia, including Alzheimer’s disease. Despite the heavy toll, patients often face substantial delays, with waiting times frequently stretching past a year. To address these systemic bottlenecks, UK Research and Innovation (UKRI) announced the Dementia Challenge programme.
Funded through the Department for Business and Trade’s Research & Development Missions Accelerator Programme (R&D MAP), the initiative is backed by up to £80 million. The primary objective is to transform National Health Service memory services so that 92% of individuals receive a timely diagnosis within 18 weeks of a referral. Officials hope the push will curb emergency hospital admissions, delay intensive care support, and grant patients earlier access to treatment and personal planning.
“We know how important it is to get a timely dementia diagnosis, so people can manage their symptoms and access life-improving support sooner. Dementia has been neglected for far too long. But this government is supporting the kind of ground breaking research projects that give us all hope of a future where loved ones stay with us for longer, with more joy and more life to live.”
Karin Smyth, Minister of State for Health
Nine Technologies Selected for Real-World NHS Testing
The programme has selected nine distinct projects to undergo real-world testing across the NHS. Departing from traditional long-term grant models, UKRI is applying a fail-fast
framework. Projects must meet strict performance milestones and demonstrate clear results to maintain ongoing financial support as part of the new funding structure.
Among the selected innovations is a project from the University of Oxford, University of Cambridge, Imperial College London, and Dementias Platform UK (DPUK). This team is introducing a panel of blood-based dementia biomarkers into routine clinical pathways at between six and ten NHS memory service sites. These biomarkers were previously validated through the Blood Biomarker Challenge-funded READ-OUT study.
Professor Vanessa Raymont, Director of DPUK and Director of R&D at Oxford Health NHS Foundation Trust, noted the potential impact of the initiative.
“Blood-based biomarkers have the potential to transform dementia diagnosis within NHS memory services. Building on the evidence generated through the READ-OUT study, this project will help us understand how these tests can be integrated into routine clinical pathways and at which point they would be most effective in supporting timely and accurate diagnoses.”
Professor Vanessa Raymont, Director of DPUK and Director of R&D at Oxford Health NHS Foundation Trust
Accelerating Assessments Through Home Platforms and Digital Tools
The eight other projects span a range of digital tools, scan optimizations, and remote assessments designed to streamline clinical workflows. At the University of Exeter, researchers are integrating a digital platform into the NHS to help people with Mild Cognitive Impairment monitor cognitive health changes at home via the PROTECT study. Professor Anne Corbett, PROTECT Study Lead, explained that the tool aims to triage thousands of waiting patients and reduce clinic burdens.
- Researchers at University College London and the UK Dementia Research Institute are working to shorten MRI brain scan durations from roughly 20 minutes down to seven minutes to increase patient access and lower costs.
- Imperial College London’s UK Dementia Research Institute Care Research & Technology Centre is developing
Minder
, a home-monitoring platform employing unobtrusive sensors and linked artificial intelligence. - Cognitron is deploying a 15-minute remote digital cognitive assessment to improve diagnostic accessibility.
- Queen Mary University of London is testing a digital diagnostic tool that evaluates how the brain processes sound using standard home computers and headphones.
- The University of Cambridge is designing an AI-enabled clinical decision support tool to analyze routine medical records and predict disease progression.
- The University of Bristol is introducing routine sleep apnoea screening within memory assessment services.
- The University of Edinburgh and NHS Research Scotland are redesigning Scottish diagnosis pathways, establishing
living labs
to test new treatments.
Clinical Reception and the Road to 2029
Dr Richard Oakley, Associate Director of Research and Innovation at Alzheimer’s Society, noted that one in three people living with dementia in the UK lack a diagnosis at any given time and miss out on crucial support.
Teams working on blood biomarkers, such as the Oxford and DPUK collaboration, have established a target timeline to build an operational blueprint for widespread NHS integration by 2029.
